Pulse Biosciences, Inc. PLSE
Set alert
52.90 USD +0.66 +1.26%
At close · Nov 2
52.90 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
51.32 Day range 53.85
12.56 52-week range 58.90
- YTD
- +285.29%
- 1 year
- +212.46%
- Open
- 52.40
- Prev close
- 52.24
- Mkt cap
- 3.77B
- Vol
- 249.69K
- Avg vol
- 503.42K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 51.32
- High
- 53.85
- Forward P/E
- -45.21
- Beta
- 1.64
- Short ratio
- 5.88
- Inst. own
- 15.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 51.08
- 200-d avg
- 31.35
- 1y target
- 62.33
6M chart
Events in this range
- May 4, 2026Earnings: -0.27; estimate -0.32; surprise 15.62%
- Aug 6, 2026Earnings: -0.36; estimate -0.31; surprise -16.13%
- Aug 10, 2026Rating: Canaccord Genuity · Buy → Buy
- Aug 17, 2026Rating: Needham · — → Buy
- Sep 9, 2026Rating: Freedom Capital Markets · — → Buy
- Sep 23, 2026Rating: BTIG · — → Buy
- Oct 6, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: Oppenheimer · Outperform → Outperform
Signals (18)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 2 months ago |
| RSI: Overbought | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jul 28, 2026 | 3 months ago |
| RSI: Overbought | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 12, 2026 | 5 months ago |
Key statistics
- Market cap
- 3.77B
- Enterprise value
- 3.63B
- Trailing P/E
- 0.00
- Forward P/E
- -45.21
- PEG ratio
- 0.00
- Price / sales
- 3183.94
- Price / book
- 37.65
- EPS (TTM)
- -1.18
- Beta
- 1.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.19M
- Revenue growth
- 0.00%
- Free cash flow
- -34.29M
- Total cash
- 101.62M
- Total debt
- 6.77M
- Return on equity
- -78.49%
- Shares outstanding
- 71.32M
- Short % of float
- 14.09%
- 50-day average
- 51.08
- 200-day average
- 31.35
Analyst view
Consensus: none
Price target (mean) 62.33 +17.8% upside
Now 52.90
- Target (low)
- 55.00
- Target (mean)
- 62.33
- Target (high)
- 73.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.2875.
Financials — quick view
PLSE Revenue — quarterly 434.00K
PLSE Net income — quarterly -24.66M
PLSE EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.3095 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.31 | -0.36 | -0.05 | -16.13% |
| May 4, 2026 | Mar 31, 2026 | -0.32 | -0.27 | +0.05 | +15.62% |
| Feb 19, 2026 | Dec 31, 2025 | -0.265 | -0.26 | +0.01 | +1.89% |
| Nov 5, 2025 | Sep 30, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Aug 12, 2025 | Jun 30, 2025 | -0.26 | -0.28 | -0.02 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 23, 2026 | BTIG | init | — | Buy |
| Sep 9, 2026 | Freedom Capital Markets | init | — | Buy |
| Aug 17, 2026 | Needham | init | — | Buy |
| Aug 10, 2026 | Canaccord Genuity | main | Buy | Buy |
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- pulsebiosciences.com
News
- Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
- Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
- Varex Imaging (NASDAQ:VREX) vs. Pulse Biosciences (NASDAQ:PLSE) Head to Head Review
- Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
- Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
- Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
- Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Your note
Sign in to keep a note on PLSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT BURKE T | Former | Sale | Dec 10, 2024 | 63,172 |
| DANAHY KEVIN PATRICK | Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 43,298 |
| DUGGAN ROBERT WILLIAM | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 49,291,700 |
| LAVIOLETTE PAUL A | Chief Executive Officer | Purchase | May 10, 2026 | 15,846 |
| UECKER DARRIN R | Chief Technology Officer | Conversion of Exercise of derivative security | Sep 16, 2025 | 284,406 |
| ZANGANEH MAHKAM | Director | Conversion of Exercise of derivative security | Feb 2, 2025 | 873,469 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.07% | 1,466,702 | 77.59M | Jun 29, 2026 |
| Bank of America Corporation | 2.04% | 1,446,611 | 76.53M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.11% | 788,640 | 41.72M | Jun 29, 2026 |
| Portolan Capital Management, LLC | 1.06% | 753,333 | 39.85M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 1.06% | 748,638 | 39.60M | Jun 29, 2026 |
| Balyasny Asset Management LP | 1.01% | 718,103 | 37.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.78% | 554,612 | 29.34M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 485,300 | 25.67M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.69% | 489,643 | 25.90M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.49% | 343,542 | 18.17M | Aug 30, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.48% | 339,453 | 17.96M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.30% | 215,880 | 11.42M | Jun 29, 2026 |